Send the following on WhatsApp
Continue to Chat德琪醫藥ATG-008聯合抗PD-1單抗藥物的TORCH-2研究的ORR達52.4%,用於治療復發/轉移性宮頸癌 https://geneonline.news/%e5%be%b7%e7%90%aa%e9%86%ab%e8%97%a5atg-008%e8%81%af%e5%90%88%e6%8a%97pd-1%e5%96%ae%e6%8a%97%e8%97%a5%e7%89%a9%e7%9a%84torch-2%e7%a0%94%e7%a9%b6%e7%9a%84orr%e9%81%9452-4%ef%bc%8c%e7%94%a8%e6%96%bc/